@ARTICLE{
author={Elsakov Pavel,Foretova Lenka,Goetz Petr,de Groot Johannes WB,van der Graaf Winette TA,Guler Gulnur,Huebner Kay,Haites Neva E,Hamann Ute,Ho Judy,Imyanitov Evgeny N,Irmejs Arvids,Purkalne Gunta,Bitina Marianna,Gardovskis Andris,Gardovskis Janis,Kirova Youlia M,Fourquet Alain,Pierga Jean-Yves,Stoppa-Lyonnet Dominique,Larizza Lidia,Lips Cornelis JM,Loman Niklas,Borg Ake,Moller Pal,Olsson Hakan,Park Jae-Gahb,Radulovic Sinisa S,Brankovic-Magic Mirjana V,Rajkumar Thangarajan,Razis Evangelia,Yannoukakos Drakoulis,Schmitt Fernando,Schmutzler Rita,Simmonds Peter D,Eccles Diana,Smeltzer Jacob,Silberstein Peter T,Lynch Henry,Weber Walter,Willemse Pax HB,Sijmons Rolf H,Wysocki Piotr J,Zajac Vladimir,Shu Zheng},
year={2007},
title={Discussion on the use of taxanes for treatment of breast cancers in BRCA1 mutations carriers},
journal={HEREDITY CANCER IN CLINICAL PRACTICE},
volume={5},
number={3},
pages={119-143},
document_type={Editorial Material},
}